Rolling review

In our opinion this is the most misread phrase in company communications, because being in rolling review sounds like being nearly approved and means almost the opposite. It is a filing convenience granted early in a programme, not a signal about the data, and a sponsor can be in rolling review for a long time with the decisive sections unfiled. The clock a reader should watch starts when the last section lands, because that is what a review deadline is measured from. So the useful question about any rolling submission is not that it is underway, it is which module is still outstanding and when the company has guided completion.

The statutory basis is section 506 of the Federal Food, Drug, and Cosmetic Act. It provides that where the regulator has determined after preliminary evaluation of clinical data that a fast track product may be effective, it "shall evaluate for filing, and may commence review of portions of, an application for the approval of the product before the sponsor submits a complete application" (21 U.S.C. 356(d)(1)). The FDA describes the practical effect on its Fast Track page: a company may submit completed sections of an application for review rather than waiting until every section is finished.

This is a United States mechanism. It says nothing about Europe, and a company in rolling review with the FDA may have made no European filing at all, which is the case we reported in Issue 9 and confirmed in Issue 11.

We have tracked one such submission since Issue 1, where we recorded the rolling NDA for COMP360 psilocybin "targeted for completion in Q4" and noted that the schedule was company-guided rather than regulator-confirmed. Issue 6 set out what to watch: "whether the final rolling NDA submission actually closes in Q4, and whether DEA rescheduling, which has no public start, can realistically clear in time for a first-half-2027 launch." That second dependency is a separate federal process and, on our reading, the softer of the two.